PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-5.40%
Cash & equivalents declining -5.40% while Medical - Pharmaceuticals shows -2.16% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
100.00%
Short-term investments yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt might see stronger near-cash accumulation as an opportunity. Check yields vs. peers.
-5.40%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -1.42%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
-98.55%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a serious red flag in ballooning receivables.
-1.93%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
21.62%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-3.21%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of -1.52%. Joel Greenblatt sees a potential liquidity edge if well allocated.
2.36%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.34%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
-6.44%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-6.44%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
17.68%
≥ 1.5x the Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees a bigger push into long-term investments. Check synergy with core business.
-4626.67%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
1028.92%
Above 1.5x Medical - Pharmaceuticals median of 0.13%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
2.53%
≥ 1.5x the Medical - Pharmaceuticals median of 1.17%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
-60.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
0.74%
Below half the Medical - Pharmaceuticals median of -0.19%. Jim Chanos might see potential stagnation or distress vs. peers.
0.44%
Payables growth above 1.5x Medical - Pharmaceuticals median of 0.27%. Jim Chanos might see a warning sign of stressed supplier payments.
-23.44%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-48.57%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-82.93%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
281.28%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-1.48%
50-75% Medical - Pharmaceuticals median of -2.33%. Mohnish Pabrai notes fewer yoy liability expansions.
-4.35%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
119.76%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-1.75%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-1.51%
Above 1.5x Medical - Pharmaceuticals median of -0.84%. Jim Chanos suspects an alarming rise in overall leverage.
No Data
No Data available this quarter, please select a different quarter.
3.98%
Below half Medical - Pharmaceuticals median of -3.67%. Jim Chanos suspects poor profitability or large dividend drains.
5.75%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos suspects a red flag if these gains are highly volatile.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
3.67%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees stronger equity growth vs. peers.
0.74%
Below half Medical - Pharmaceuticals median of -0.09%. Jim Chanos suspects a major slowdown or distress.
380140.00%
≥ 1.5x Medical - Pharmaceuticals median of 0.00%. Joel Greenblatt sees bigger push into investments vs. peers.
-38.23%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
-121.00%
Above 1.5x Medical - Pharmaceuticals median 0.00%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.